Current Clinical Treatments of AIDS

Advances in Pharmacology

Volumn 56, Issue , 2008, Pages 27-73

  Murphy, Erin Margaret ^a,b   Jimenez, Humberto R ^a,b   Smith, Stephen M ^a,b,c  

^a ST MICHAEL S MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; REVIEW; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LONG-TERM CARE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 37248999359     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(07)56002-3     Document Type: Review

References (156)

1. Anonymous. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. In: U.D.o.H.a.H. Services (Ed) (2006)
2. Anonymous. ClinicalTrials.gov. In: N.I.o. Health (Ed) (2007)
3. Agenerase. "Prescribing Information," (2006), GlaxoSmithKline, Research Triangle Park, NC
4. Alvarez D., Dieterich D.T., Brau N., Moorehead L., Ball L., and Sulkowski M.S. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J. Viral Hepat. 13 10 (2006) 683-689
5. Aptivus. "Prescribing Information," (2005), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
6. Back D., Gibbons S., and Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28 3 (2006) 468-473
7. Balani S.K., Kauffman L.R., deLuna F.A., and Lin J.H. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab. Dispos. 27 1 (1999) 41-45
8. Baldwin J.R., Boron M.T., Wang Y., Schneck D.W., and Hopkins N.K. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (1998) Abstract 649
9. Balzarini J., Lee C.K., Herdewijn P., and De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. 266 32 (1991) 21509-21514
10. Barreiro P., Rodríguez-Novoa S., Labarga P., Ruiz A., Jiménez-Nácher I., Martín-Carbonero L., Gonzalez-Lahoz J., and Soriano V. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J. Infect. Dis. 195 7 (2007) 973-979
11. Behrens G., Dejam A., Schmidt H., Balks H.J., Brabant G., Korner T., Stoll M., and Schmidt R.E. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13 10 (1999) F63-F70
12. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., van Der Horst C., Hamrick Jr. H.J., Powderly W.G., and Mundy L.M. Sex differences in nevirapine rash. Clin. Infect. Dis. 32 1 (2001) 124-129
13. Blum M.R., Liao S.H., Good S.S., and de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 2A (1988) 189-194
14. Boelaert J.R., Dom G.M., Huitema A.D., Beijnen J.H., and Lange J.M. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. AIDS 16 16 (2002) 2221-2223
15. Boffito M., Acosta E., Burger D., Fletcher C.V., Flexner C., Garaffo R., Gatti G., Kurowski M., Perno C.F., Peytavin G., Regazzi M., and Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir. Ther. 10 3 (2005) 375-392
16. Brinkman K., ter Hofstede H.J., Burger D.M., Smeitink J.A., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12 14 (1998) 1735-1744
17. Brothers C., Wannamaker P., Sutherland-Phillips D., and Hernandez J. Lower reported rate of suspected hypersensitivity reaction (HSR) to abacavir (ABC) among black patients. Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006) Abstract H-1065
18. Browne M.J., Mayer K.H., Chafee S.B., Dudley M.N., Posner M.R., Steinberg S.M., Graham K.K., Geletko S.M., Zinner S.H., Denman S.L., et al. 2′,3′,-didehydro-3′,-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. J. Infect. Dis. 167 1 (1993) 21-29
19. Burger D.M., Hugen P.W., Kroon F.P., Groeneveld P., Brinkman K., Foudraine N.A., Sprenger H., Koopmans P.P., and Hekster Y.A. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 12 15 (1998) 2080-2082
20. Cadman J. Efavirenz pregnancy warning. GMHC Treat. Issues 12 3 (1998) 12
21. Campbell T.B., Shulman N.S., Johnson S.C., Zolopa A.R., Young R.K., Bushman L., Fletcher C.V., Lanier E.R., Merigan T.C., and Kuritzkes D.R. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin. Infect. Dis. 41 2 (2005) 236-242
22. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., and Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 7 (1998) F51-F58
23. Castagna A., Danise A., Menzo S., Galli L., Gianotti N., Carini E., Boeri E., Galli A., Cernuschi M., Hasson H., Clementi M., and Lazzarin A. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 20 6 (2006) 795-803
24. Catanzaro L.M., Slish J.C., DiCenzo R., and Morse G.D. Drug interactions with antiretrovirals. Curr. HIV/AIDS Rep. 1 2 (2004) 89-96
25. Cheeseman S.H., Hattox S.E., McLaughlin M.M., Koup R.A., Andrews C., Bova C.A., Pav J.W., Roy T., Sullivan J.L., and Keirns J.J. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37 2 (1993) 178-182
26. Chittick G.E., Gillotin C., McDowell J.A., Lou Y., Edwards K.D., Prince W.T., and Stein D.S. Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 19 8 (1999) 932-942
27. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., and Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94 24 (1997) 13193-13197
28. Companies A.s.P. Medicines in development for HIV/AIDS (2006)
29. Cooper D., Steinhart C., and Ward D. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. XVI International AIDS Conference (2006) Abstract TUPE0061
30. Crixivan. "Prescribing Information," (2006), Merck & Co, Inc., Whitehouse Station, NJ
31. Crowe S., Cooper D.A., and Chambers D. Antiviral therapies for HIV: Managing HIV. Med. J. Aust. 164 (1996) 290-295
32. Cundy K.C., Sueoka C., Lynch G.R., Griffin L., Lee W.A., and Shaw J.P. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob. Agents Chemother. 42 3 (1998) 687-690
33. D'Aquila R.T., Hughes M.D., Johnson V.A., Fischl M.A., Sommadossi J.P., Liou S.H., Timpone J., Myers M., Basgoz N., Niu M., and Hirsch M.S. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. national institute of allergy and infectious diseases AIDS clinical trials group protocol 241 investigators. Ann. Intern. Med. 124 12 (1996) 1019-1030
34. Davey Jr. R.T., Chaitt D.G., Reed G.F., Freimuth W.W., Herpin B.R., Metcalf J.A., Eastman P.S., Falloon J., Kovacs J.A., Polis M.A., Walker R.E., and Masur H. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40 7 (1996) 1657-1664
35. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8 2 (1995) 200-239
36. Deeks S.G. Antiretroviral agents: The next generation. AIDS Clin. Care 10 5 (1998) 33-36 39-40
37. Deeks S.G., and Volberding P.A. HIV-1 protease inhibitors. AIDS Clin. Rev. (1997) 145-185
38. DeJesus E., Herrera G., Teofilo E., Gerstoft J., Buendia C.B., Brand J.D., Brothers C.H., Hernandez J., Castillo S.A., Bonny T., Lanier E.R., and Scott T.R. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39 7 (2004) 1038-1046
39. Delfraissy J.-F., Flandre P., and Delaugerre C. MONARK trial: 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compated to LPV/r + zidovudine/lamivudine in antiretroviral-naive patients. International AIDS Conference (2006)
40. Dolin R., Amato D.A., Fischl M.A., Pettinelli C., Beltangady M., Liou S.H., Brown M.J., Cross A.P., Hirsch M.S., Hardy W.D., et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS clinical trials group. Arch. Intern. Med. 155 9 (1995) 961-974
41. Dudley M.N., Graham K.K., Kaul S., Geletko S., Dunkle L., Browne M., and Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166 3 (1992) 480-485
42. Easterbrook P.J., Waters A., Murad S., Ives N., Taylor C., King D., Vyakarnam A., and Thorburn D. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 4 4 (2003) 321-324
43. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., Babiker A., Burman W., Clumeck N., Cohen C.J., Cohn D., and Cooper D. CD4 + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355 22 (2006) 2283-2296
44. Emtriva. "Prescribing Information," (2006), Gilead Sciences, Inc., Foster City, CA
45. Epivir. "Prescribing Information," (2006), GlaxoSmithKline, Research Triangle Park, NC
46. Eron Jr. J., Yeni P., Gathe Jr. J., Estrada V., DeJesus E., Staszewski S., Lackey P., Katlama C., Young B., Yau L., Sutherland-Phillips D., Wannamaker P., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 368 9534 (2006) 476-482
47. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., Kuritzkes D.R., Fallon M.A., and Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 + cells per cubic millimeter. North American HIV working party. N. Engl. J. Med. 333 25 (1995) 1662-1669
48. Falloon J., Piscitelli S., Vogel S., Sadler B., Mitsuya H., Kavlick M.F., Yoshimura K., Rogers M., LaFon S., Manion D.J., Lane H.C., and Masur H. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30 2 (2000) 313-318
49. Farthing C., Khanlou H., and Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. International AIDS Society Conference on HIV Pathogenesis and Treatment (2003)
50. Ferrari A., Coccia C.P., Bertolini A., and Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol. Res. 50 6 (2004) 551-559
51. Fletcher C. Navigating the concentration curves: Pharmacologic considerations in the treatment of HIV. Adv. Stud. Med. 6 9B (2006) S853-S872
52. Foster R.H., and Faulds D. Abacavir. Drugs 55 5 (1998) 729-736 discussion 737-738
53. Freimuth W.W., Chuang-Stein C.J., Greenwald C.A., Cox S.R., Edge-Padbury B.A., Carberry P.A., and Wathen L.K. Delavirdine (DLV) + didanosine (ddI) combination therapy has sustained surrogate marker response in advanced HIV-1 population (abstract). 3rd Conf Retro Opportun Infect (1996) Abstract 163
54. Fung H.B., Stone E.A., and Piacenti F.J. Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin. Ther. 24 10 (2002) 1515-1548
55. Fuzeon. "Prescribing Information," (2004), Roche Laboratories, Nutley, NJ
56. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., Lu B., McColl D., Chuck S., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354 3 (2006) 251-260
57. Gao W.Y., Shirasaka T., Johns D.G., Broder S., and Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91 5 (1993) 2326-2333
58. Gathe Jr. J.C., Ive P., Wood R., Schurmann D., Bellos N.C., DeJesus E., Gladysz A., Garris C., and Yeo J. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18 11 (2004) 1529-1537
59. Greeson J.M., Sanford B., and Monti D.A. St. John's wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl.) 153 4 (2001) 402-414
60. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., Wolfe A., Egbertson M., Bourgeois M., Melamed J., Wai J.S., Young S., et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 99 10 (2002) 6661-6666
61. Gulick R.M., Ribaudo H.J., Shikuma C.M., Lustgarten S., Squires K.E., Meyer III W.A., Acosta E.P., Schackman B.R., Pilcher C.D., Murphy R.L., Maher W.E., Witt M.D., et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350 18 (2004) 1850-1861
62. Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., De Gruttola V., Pollard R.B., Merigan T.C., et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: An adult aids clinical trials group study. J. Infect. Dis. 192 11 (2005) 1931-1942
63. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., and Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team. N. Engl. J. Med. 337 11 (1997) 725-733
64. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., and Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 5453 (2000) 646-650
65. Hicks C., DeJesus E., Sloan L., et al. Efficacy and safety of once-daily boosted fosamprenavir/ritonavir with abacavir/lamivudine fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758. 8th International Congress on Drug Therapy in HIV Infection (2006) Abstract P2
66. Hirani V.N., Raucy J.L., and Lasker J.M. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab. Dispos. 32 12 (2004) 1462-1467
67. Hoetelmans R.M., van Heeswijk R.P., Profijt M., Mulder J.W., Meenhorst P.L., Lange J.M., Reiss P., and Beijnen J.H. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 12 17 (1998) F211-F216
68. Hoggard P.G., Veal G.J., Wild M.J., Barry M.G., and Back D.J. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob. Agents Chemother. 39 6 (1995) 1376-1378
69. Hoggard P.G., Kewn S., Barry M.G., Khoo S.H., and Back D.J. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41 6 (1997) 1231-1236
70. Honda M., Yasuoka A., Aoki M., and Oka S. A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Intern. Med. 38 3 (1999) 302-303
71. Huisman M.T., Smit J.W., and Schinkel A.H. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14 3 (2000) 237-242
72. Invirase. "Prescribing Information," (2005), Roche Laboratories, Nutley, NJ
73. Jensen-Fangel S., Justesen U.S., Black F.T., Pedersen C., and Obel N. The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients. HIV Med. 4 1 (2003) 48-52
74. Johnson M., Grinsztejn B., Rodriguez C., Coco J., DeJesus E., Lazzarin A., Lichtenstein K., Rightmire A., Sankoh S., and Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19 7 (2005) 685-694
75. Johnson M.A., Gathe Jr. J.C., Podzamczer D., Molina J.M., Naylor C.T., Chiu Y.L., King M.S., Podsadecki T.J., Hanna G.J., and Brun S.C. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43 2 (2006) 153-160
76. Kahn J.O., Lagakos S.W., Richman D.D., Cross A., Pettinelli C., Liou S.H., Brown M., Volberding P.A., Crumpacker C.S., Beall G., et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS clinical trials group. N. Engl. J. Med. 327 9 (1992) 581-587
77. Kaletra. "Prescribing Information," (2006), Abbott Laboratories, North Chicago, IL
78. Kaul S., Bassi K., Damle B., Xie J., Gale J., Kearney B., and Hanna G. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), the enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral. Program and abstracts at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (2003) Abstract A-1616
79. Kearney B., Flaherty J., Wolf F., et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects. Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection (2001)
80. Kilby J.M., and Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348 22 (2003) 2228-2238
81. Kilby J.M., Hill A., and Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 3 2 (2002) 97-104
82. Kopp J.B., Miller K.D., Mican J.A., Feuerstein I.M., Vaughan E., Baker C., Pannell L.K., and Falloon J. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 127 2 (1997) 119-125
83. Krikorian S.A., and Rudorf D.C. Drug-drug interactions and HIV therapy: What should pharmacist know?. J. Pharm. Pract. 18 (2005) 278-294
84. la Porte C.J., de Graaff-Teulen M.J., Colbers E.P., Voncken D.S., Ibanez S.M., Koopmans P.P., Hekster Y.A., and Burger D.M. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Br. J. Clin. Pharmacol. 58 6 (2004) 632-640
85. Lambert J.S., Seidlin M., Reichman R.C., Plank C.S., Laverty M., Morse G.D., Knupp C., McLaren C., Pettinelli C., Valentine F.T., et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N. Engl. J. Med. 322 19 (1990) 1333-1340
86. Lee W.A., and Martin J.C. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res. 71 2-3 (2006) 254-259
87. Lertora J.J., Rege A.B., Greenspan D.L., Akula S., George W.J., Hyslop Jr. N.E., and Agrawal K.C. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 56 3 (1994) 272-278
88. Liedtke M.D., Lockhart S.M., and Rathbun R.C. Anticonvulsant and antiretroviral interactions. Ann. Pharmacother. 38 3 (2004) 482-489
89. Lonergan J.T., Behling C., Pfander H., Hassanein T.I., and Mathews W.C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin. Infect. Dis. 31 1 (2000) 162-166
90. MacArthur R.D., Novak R.M., Peng G., Chen L., Xiang Y., Hullsiek K.H., Kozal M.J., van den Berg-Wolf M., Henely C., Schmetter B., and Dehlinger M. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): A long-term randomised trial. Lancet 368 9553 (2006) 2125-2135
91. Malik A., Abraham P., and Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J. Infect. 51 2 (2005) E61-E65
92. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., and Christiansen F.T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 9308 (2002) 727-732
93. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., and Chavin K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. Jama 290 11 (2003) 1500-1504
94. Markowitz M., Conant M., Hurley A., Schluger R., Duran M., Peterkin J., Chapman S., Patick A., Hendricks A., Yuen G.J., Hoskins W., Clendeninn N., and Ho D.D. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177 6 (1998) 1533-1540
95. McDonald C.K., and Kuritzkes D.R. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157 9 (1997) 951-959
96. McDowell J.A., Chittick G.E., Stevens C.P., Edwards K.D., and Stein D.S. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44 6 (2000) 1686-1690
97. Merry C., Barry M.G., Mulcahy F., Ryan M., Heavey J., Tjia J.F., Gibbons S.E., Breckenridge A.M., and Back D.J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11 4 (1997) F29-F33
98. Miralles Alvarez C., Torres Perea R., SanzSanz J., Ocaña I., Hervás R., Vergara A., Lorenzo A., Dalmau D., Cervantes M., Knobel H., de la Fuente García B., Flores Cid J., et al. Identification and follow up of adverse events related to NRTI use that in the clinical practice causes its substitution for tenofovir DF (RECOVER study). 15th International AIDS Conference (2004)
99. Montaner J.S., Reiss P., Cooper D., Vella S., Harris M., Conway B., Wainberg M.A., Smith D., Robinson P., Hall D., Myers M., and Lange J.M. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, the Netherlands, Canada and Australia study. Jama 279 12 (1998) 930-937
100. Moore K.H., Yuen G.J., Raasch R.H., Eron J.J., Martin D., Mydlow P.K., and Hussey E.K. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59 5 (1996) 550-558
101. Moreno A., Quereda C., Moreno L., Perez-Elías M.J., Muriel A., Casado J.L., Antela A., Dronda F., Navas E., Bárcena R., and Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Ther 9 1 (2004) 133-138
102. Morse C.G., and Kovacs J.A. Metabolic and skeletal complications of HIV infection: The price of success. Jama 296 7 (2006) 844-854
103. Murata H., Hruz P.W., and Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275 27 (2000) 20251-20254
104. Negredo E., Molto J., Burger D., Viciana P., Ribera E., Paredes R., Juan M., Ruiz L., Puig J., Pruvost A., Grassi J., Masmitja E., et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18 3 (2004) 459-463
105. Norvir. "Prescribing Information," (2006), Abbott Laboratories, North Chicago, IL
106. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18 1 (2004) 51-58
107. Podzamczer D., Ferrer E., Sanchez P., Gatell J.M., Crespo M., Fisac C., Lonca M., Sanz J., Niubo J., Veloso S., Llibre J.M., Barrufet P., et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-Week results of a randomized study. J. Acquir. Immune Defic. Syndr. 44 2 (2006) 139-147
108. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., Ho D.D., Mo H., Gorman III R.R., Dueweke T.J., Thaisrivongs S., and Tarpley W.G. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41 5 (1997) 1058-1063
109. Prezista. "Prescribing Information," (2006), Tibotec Therapeutics, Raritan, NJ
110. Quart B.D., Chapman S.K., Peterkin J., Webber S., and Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343-a novel HIV protease inhibitor. Second National Conference on Human Retroviruses and Related Infections (1995) Abstract LB3
111. Ray A.S., Olson L., and Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48 4 (2004) 1089-1095
112. Reeves I., Fishaer M., and Churchill D. Clinical utility of HLA-B*5701 testing in a UK clinic cohort. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (2006) Abstract 667a
113. Rescriptor. "Prescribing Information," (2006), Pharmacia & Upjohn Company, Kalamazoo, MI
114. Retrovir. "Prescribing Information," (2006), GlaxoSmithKline, Research Triangle Park, NC
115. Reyataz. "Prescribing Information," (2006), Bristol-Myers Squibb, Princeton, NJ
116. Richman D.D., Fischl M.A., Grieco M.H., Gottlieb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Hirsch M.S., et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317 4 (1987) 192-197
117. Riddler S.A., Haubrich R., DiRienzo G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Havlir D., Mellors J.W., et al. A prospective, randomized phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. International AIDS Conference (2006)
118. Robbins G.K., De Gruttola V., Shafer R.W., Smeaton L.M., Snyder S.W., Pettinelli C., Dube M.P., Fischl M.A., Pollard R.B., Delapenha R., Gedeon L., van der Horst C., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349 24 (2003) 2293-2303
119. Rodriguez-Torres M., Torriani F.J., Soriano V., Borucki M.J., Lissen E., Sulkowski M., Dieterich D., Wang K., Gries J.M., Hoggard P.G., and Back D. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: Results of a randomized clinical study. Antimicrob. Agents Chemother. 49 10 (2005) 3997-4008
120. Roszko P.J., Curry K., Brazina B., Cohen A., Turkie E.L., Sabo J.P., MacGregor T.R., and McCallister S. Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r). International AIDS Society 2nd Conferene of Pathogenesis and Treatment (2003) Abstract No. 865
121. Ruane P., Luber A., Wire M.B., et al. Plasma amprenavir pharmacokinetics and safety following co-administration of fosamprenavir with a reduced ritonavir dose once daily (COL 10053). Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004) Abstract A-449
122. Saint-Marc T., and Touraine J.L. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 13 15 (1999) 2188-2189
123. Schaaf B., Aries S.P., Kramme E., Steinhoff J., and Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. 37 3 (2003) e41-e43
124. Schewe C.K., Maserati R., Wassmer G., Adam A., and Weitner L. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. Clin. Infect. Dis. 42 1 (2006) 145-147
125. Scott L.J., and Perry C.M. Delavirdine: A review of its use in HIV infection. Drugs 60 6 (2000) 1411-1444
126. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.M., Kati W., Stewart K., Lal R., Hsu A., Betebenner D., Korneyeva M., et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42 12 (1998) 3218-3224
127. Solas C., Poizot-Martin I., Drogoul M.P., Ravaux I., Dhiver C., Lafeuillade A., Allegre T., Mokhtari M., Moreau J., Lepeu G., Petit N., Durand A., et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br. J. Clin. Pharmacol. 57 4 (2004) 436-440
128. Sosa N., Hill-Zabala C., Dejesus E., Herrera G., Florance A., Watson M., Vavro C., and Shaefer M. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. 40 4 (2005) 422-427
129. Squires K., Lazzarin A., Gatell J.M., Powderly W.G., Pokrovskiy V., Delfraissy J.F., Jemsek J., Rivero A., Rozenbaum W., Schrader S., Sension M., and Vibhagool A. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36 5 (2004) 1011-1019
130. Sustiva. "Prescribing Information," (2006), Bristol-Myers Squibb, Princeton, NJ
131. Swindells S., Wilkin T., DiRienzo G., et al. A prospective, open-label trial of regimen simplifications to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). Conference on Retroviruses and Opportunistic Infection (2006)
132. Taburet A.M., Naveau S., Zorza G., Colin J.N., Delfraissy J.F., Chaput J.C., and Singlas E. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin. Pharmacol. Ther. 47 6 (1990) 731-739
133. Taburet A.M., Piketty C., Chazallon C., Vincent I., Gerard L., Calvez V., Clavel F., Aboulker J.P., and Girard P.M. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48 6 (2004) 2091-2096
134. Tashima K.T., Bausserman L., Alt E.N., Aznar E., and Flanigan T.P. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin. Trials 4 1 (2003) 29-36
135. Tavassoli N., Bagheri H., Sommet A., Delpierre C., Marion-Latard F., Massip P., Aquilina C., Bonnet E., Obadia M., Labau E., Montastruc J.L., and Bernard J. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Pharmacotherapy 26 2 (2006) 154-161
136. Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., and Yarasheski K.E. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14 4 (2000) F63-F67
137. van Leeuwen R., Lange J.M., Hussey E.K., Donn K.H., Hall S.T., Harker A.J., Jonker P., and Danner S.A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study. AIDS 6 12 (1992) 1471-1475
138. van Leth F., Hassink E., Phanuphak P., Miller S., Gazzard B., Cahn P., Wood R., Squires K., Katlama C., Santos B., Robinson P., van Leeuwen R., et al. Results of the 2NN study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Conference on Retroviruses and Opportunistic Infections (2003)
139. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo U.G., van der Westhuizen I.P., Malan D.R., Johnson M.A., Santos B.R., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 363 9417 (2004) 1253-1263
140. Vfend. "Prescribing Information," (2006), Roerig, Division of Pfizer, Inc., New York, NY
141. VidexEC. "Prescribing Information," (2006), Bristol-Myers Squibb, Princeton, NJ
142. Viracept. "Prescribing Information," (2006), Agouron Pharmaceuticals, Inc., La Jolla, CA
143. Viramune. "Prescribing Information," (2005), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
144. Viread. "Prescribing Information," (2006), Gilead Sciences, Inc., Foster City, CA
145. Walker U.A., Setzer B., and Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16 16 (2002) 2165-2173
146. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P., Johnson M., Johnson D., Lalonde R., Japour A., Brun S., and Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346 26 (2002) 2039-2046
147. Walmsley S., Leith J., Katlama C., Arasteh K., Pierone G., Blick G., Lazzarin A., Johnson M., Samuels C., Jones P., Chaves R., Quinson A., et al. Pharmacokinetics and safety of Tipranavir/Ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): Interim analysis of BI 1182.51. 15th International AIDS Conference (2004) WeOrB1236
148. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., LaLota M., Dickinson G., Schwarcz S., Torian L., Wendell D., Paul S., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189 12 (2004) 2174-2180
149. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J. Infect. Dis. 192 6 (2005) 958-966
150. Yarchoan R., Mitsuya H., Myers C.E., and Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321 11 (1989) 726-738
151. Yeh K.C., Deutsch P.J., Haddix H., Hesney M., Hoagland V., Ju W.D., Justice S.J., Osborne B., Sterrett A.T., Stone J.A., Woolf E., and Waldman S. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42 2 (1998) 332-338
152. Yeni P., Cooper D.A., Aboulker J.P., Babiker A.G., Carey D., Darbyshire J.H., Floridia M., Girard P.M., Goodall R.L., Hooker M.H., Mijch A., Meiffredy V., et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: Open-label randomised trial. Lancet 368 9532 (2006) 287-298
153. Youle M., Gerstoft J., Fox Z., et al. The final week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ ritonavir (1000/100 mg bid): The MaxCmin2 trial. Program and abstracts of the 9th European AIDS Conference (EACS), 1st EACS Resistance & Pharmacology Workshop (2003) Abstract F11/3
154. Zerit. "Prescribing Information," (2006), Bristol-Myers Squibb, Princeton, NJ
155. Zhou S., Chan E., Pan S.Q., Huang M., and Lee E.J. Pharmacokinetic interactions of drugs with St John's wort. J. Psychopharmacol. 18 2 (2004) 262-276
156. Zucker S.D., Qin X., Rouster S.D., Yu F., Green R.M., Keshavan P., Feinberg J., and Sherman K.E. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA 98 22 (2001) 12671-12676